Monthly Archives: December 2014

Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation

Posted on December 16, 2014

Northvale, New Jersey, Tuesday, December 16, 2014: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP) today announced the continued expansion of Elite’s intellectual property protection covering the Company’s abuse deterrent technology with the issuance of a second Canadian Patent, … Continue reading →

Share
Posted in Press Releases | Comments Off on Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation

ELITE PHARMACEUTICALS REPORTS SUCCESSFUL PIVOTAL BIOEQUIVALENCE STUDY FOR ABUSE-DETERRENT OXYCODONE PRODUCT ELI-201

Posted on December 3, 2014

Northvale, New Jersey, Wednesday, December 03, 2014: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite’s twice daily abuse-deterrent oxycodone product which utilizes Elite’s proprietary pharmacological abuse-deterrent … Continue reading →

Share
Posted in Press Releases | Comments Off on ELITE PHARMACEUTICALS REPORTS SUCCESSFUL PIVOTAL BIOEQUIVALENCE STUDY FOR ABUSE-DETERRENT OXYCODONE PRODUCT ELI-201